Media Newsroom of

Memgen

12 Greenway Plaza (Suite 1100)
Houston, TX 77046

Memgen is a cancer immunotherapy company focused on creating drugs that harness the power of the immune system to cure cancer.

John Poulos Appointed to Memgen's Board of Directors

John Poulos Appointed to Memgen's Board of Directors

Memgen, a private biotechnology company developing novel treatments for cancer and COVID-19, today announced that John Poulos has joined the company's Board of Directors. "I am very pleased to join the board of Memgen at this transformational time in the…

Memgen Announces Addition of Leading Vaccine Expert to Scientific Advisory Board

Memgen Announces Addition of Leading Vaccine Expert to Scientific Advisory Board

Memgen, Inc., a private biotechnology company developing innovative immune-based drugs for the control of infectious diseases and cancer, announced today that Dr. Thomas Monath, a world-renowned virologist and vaccinologist, has joined the Company’s Scientific Advisory Board. The addition of Dr.…

Memgen Announces Research to Be Presented at 2020 American Association of Cancer Research (AACR) Meeting

Memgen Announces Research to Be Presented at 2020 American Association of Cancer Research (AACR) Meeting

Memgen, a private biotechnology company developing novel treatments for cancer and COVID-19, announced an abstract and upcoming poster presentation at the 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020. The presentation summarizes preclinical…

Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies

Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies

Memgen, a private biotechnology company developing innovative immuno-oncology drugs and immune therapeutics, announced today that it has entered into technology licensing agreements with the Moffitt Cancer Center, a premier center for cancer research and care. The agreements cover intellectual property…

Memgen Announces Addition to Board of Directors

Memgen Announces Addition to Board of Directors

Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that Christopher Pagano has joined the company’s Board of Directors. “I am delighted to join the board of Memgen at this exciting time in the company’s development,” noted Mr.…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login